Crown Bioscience announced collaboration with Jiangsu Qyun Bio-Pharmaceutical to develop antibody. The goal of the collaboration is to develop a less toxic CTLA-4 antibody and better combination strategies to overcome the immunological adverse effects due to T cell activation and proliferation observed in a minority of patients treated with anti-CTLA-4 immunotherapies.
As part of the collaboration agreement CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody. 10B10 is a humanized anti-CTLA-4 antibody with higher binding affinity and in vitro T cell stimulation than ipilimumab, the first immune checkpoint blockade antibody targeting CTLA-4 to receive FDA approval for the treatment of melanoma. The two antibodies have equivalent activity in T cell activation and tumor growth suppression but a different binding epitope and pharmacokinetic profile.
CrownBio CEO, Jean-Pierre Wery said that the collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical Co. Ltd is indicative of their focus on innovation, and enhances their portfolio in immuno-oncology. Moreover, this partnership highlights CrownBio’s commitment to develop therapies that could significantly impact the way cancer is treated.
Jiangsu Qyun Bio-Pharmaceuticals CEO, Qiu Jiwan said that CrownBio is the ideal partner to progress candidate compounds to IND and clinical development thanks to their recognized in vivo pharmacology expertise and the high quality and standards of their operations, representing the perfect match to our know how in antibody engineering, cell line construction, and experience in GMP production management, quality control, clinical research, and regulatory affairs.